Defendant

Medical IP Holdings LP

1 case as defendant.

Company profile

Medical IP Holdings LP is a privately held entity, appearing as a defendant in U.S. patent litigation. While specific details on Medical IP Holdings LP itself are limited, it is understood to be related to Medical IP (also stylized as MEDICAL IP), a South Korean operating company founded in 2015 as a spin-off from Seoul National University Hospital. Medical IP is headquartered in Seoul, South Korea, and is venture capital-backed.

The core business of the associated operating company, Medical IP, revolves around developing AI and 3D medical imaging analysis platforms and solutions. Its offerings include FDA-cleared software for whole-body composition analysis, advanced medical education using digital twins, and patient-centric AI for health and longevity. Key products such as MEDIP Pro, MEDIP Box, DeepCatch X (for CT quantification and cardiovascular imaging analysis), and DeepFore (a liver cancer prediction solution) utilize AI to detect body components and lesions from medical images, extracting quantitative data. The company also applies its technology to 3D printing of anatomical structures for surgical simulation, training, education, and patient consultation.

Medical IP Holdings LP's patent litigation posture is that of a defendant operating company. The entity has been tracked in one case and has not initiated any lawsuits as a plaintiff. [Case Data] This single case, Lone Star SCM Systems, LP v. Medical IP Holdings LP, was filed on November 13, 2023, in the North Carolina Western District Court. [Case Data] Lone Star SCM Systems, LP is characterized as a patent assertion entity (NPE) that asserts patents related to radio frequency identification (RFID) and data capture technology.

The sole notable case for Medical IP Holdings LP is the aforementioned suit brought by Lone Star SCM Systems, LP. [Case Data] This indicates Medical IP Holdings LP is defending against a patent infringement claim by an NPE. The operating company, Medical IP, has secured FDA clearances for its medical imaging solutions and is actively expanding its presence, including into the U.S. market, making it a potential target for patent assertion entities.